Preclinical is the bucket where peptide research lives between mechanism and the clinic. Coverage on this site has tracked rodent, pig, and non-human-primate readouts for compounds that are not yet in human trials but carry the strongest claims about the next generation of peptide therapeutics.
Lead programs covered here in 2026: the Lilly + Indiana Biosciences quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) with rodent data heading to ADA 2026 May 29, the DiMarchi/Tschöp/Müller GLP-1R/GIPR/PPARα/γ/δ peptide-drug conjugate published in Nature April 30, the BMC Biotechnology DualPep-ALO cell-penetrating peptide for hair growth, the Aivocode CAQK tetrapeptide for traumatic brain injury (EMBO Mol Med, October 2025), the UTHealth BLMP6 fibulin-4 peptide for metastatic triple-negative breast cancer, and the early atherosclerotic-plaque-prevention work with GLP-1.
Stories here cover animal-model efficacy, mechanism-of-action work, and IND-enabling readouts. See #animal-models, #mechanism, and #ind for adjacent threads.
Eli Lilly, with the Indiana Biosciences Research Institute, has disclosed an ADA Scientific Sessions Late-Breaking Poster slot (Poster 2839-LB, May 29) for a single peptide molecule that simultaneously activates five receptors: GLP-1, GIP, glucagon, amylin, and calcitonin. Lead investigator Jonathan Douros, PhD, will present rodent data showing weight-loss superiority over retatrutide in Lilly-sponsored animal studies. The compound is distinct from the DiMarchi/Tschöp/Müller GLP-1R/GIPR/PPARα/γ/δ quintuple agonist published in Nature on April 30 — that one is a peptide-drug conjugate combining GLP-1/GIP with the pan-PPAR agonist lanifibranor, while the Lilly + Indiana Biosciences molecule appears to be a single peptide hitting all five receptors directly. Both signal that the obesity-pharmacology ceiling is moving past the triple-agonist generation.
A 2026 BMC Biotechnology paper introduces DualPep-ALO, a novel synthetic cell-penetrating peptide engineered to promote hair growth by restoring the follicular microenvironment and stimulating regenerative pathways. In preclinical models, DualPep-ALO showed potent antioxidant, anti-inflammatory, and pro-regenerative effects, restoring follicular vitality through multimodal biological pathways. The paper supports the peptide's potential as a topical CPP-based agent for hair loss, warranting further clinical investigation. The work joins a 2026 wave of peptide-led hair-growth research alongside copper-peptide GHK-Cu's surge in the cosmetic and longevity-clinic space and the broader 'peptide therapy' search trend that Drexel's May 5 Q&A flagged as a 1,016% YoY rise for GHK-Cu specifically.
A study in Scientific Reports found that early intervention with tirzepatide or semaglutide significantly reduced atherosclerotic plaque formation in ApoE-knockout mice, suggesting GLP-1 drugs may have preventive cardiovascular benefits beyond their metabolic effects when initiated before disease progression.